Asset scouting
Find the asset worth licensing first: Sleuth scores every asset that fits your brief on your own criteria and checks who still holds the rights.
Use it when
- You're on a pharma BD or search and evaluation team with a licensing brief.
- You need a ranked shortlist your team can defend, with the reason behind every score.
- You want to know what's already taken before anyone makes a call.
What to have ready
What you want (the modality, stage, indication, and rights), the decision it feeds, and what matters most to your team.
How it runs
- Describe what you're looking for. Your brief, in your own words.
- Decide what counts. Pick the criteria, such as white space, target validation, early efficacy and safety, and deal comps, and how much each one counts.
- Shape the plan. Sleuth shows its three steps: build the landscape, define the criteria, and score and rank. Narrow the scope or change a criterion before it runs.
- Get the analysis. A ranked shortlist and a recommendation, the score behind every asset, and the full landscape as a dataset.
What you get
| Your question | What Sleuth gives you |
|---|---|
| What's out there that fits? | Every asset in your scope, at companies of every size and in every region, each counted once with its development stage checked. |
| Is it still available? | Each asset's partnering status, checked at the source: unpartnered, licensed out, held with shared rights, or looking for a partner. |
| How does it score on what we care about? | Your criteria, in your own words where you want, with set levels behind each score and the fact that decided it. |
| Which one do we call first? | A ranked shortlist with a recommendation, what other buyers paid for assets like these, and what to ask each company before talks start. |
A finished example
Which early T-cell engager should a mid-sized pharma license first? Sleuth says CLN-049. Sleuth scored 150 early T-cell engagers in oncology on seven criteria and checked who holds the rights. Four of the top ten were already taken. See the full example
Questions
Will it find assets our usual searches miss?
Sleuth searches companies of every size, including private companies and programs out of China, and counts each asset once. China coverage
Can we use our own criteria?
Yes. Name them in your own words, set what each score level means, and choose how much each one counts.
What if an asset hasn't reported data yet?
Sleuth leaves that score blank instead of scoring it low, so missing data doesn't push an asset down the list.
Does it include assets that are already partnered?
Yes, marked as licensed out or held with shared rights, so you can see what's taken before you call. In the example, four of the top ten were.
How early can the assets be?
You set the stages in your brief. The example covers first-in-human to Phase 1/2.
Does it show what other buyers paid?
Yes. Deal comps can be one of your criteria, with the deals done on each target and the largest upfront paid.
The plan shows the size of the job before anything runs: rows times analytical columns is the credits it will use. Each asset scored on each criterion is an analytical cell, so a wider scope or more criteria uses more credits. How credits work
Next questions on the same project
Asset assessment works out what your top pick is worth. Monitoring tells you when a shortlisted asset changes hands or reports data.
Updated November 9, 2026